September 5, 2012
Astellas Pharma announced on September 3 that its anti-cancer agent enzalutamide was approved on August 31 by the US FDA for the treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel. It is scheduled to be...read more